As the non-muscle invasive space is carved up, Aura tries to seize part of it.

At least 15 dual-payload ADCs will be discussed.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.

Ikena, Senti and others look to clinical presentations at AACR.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.

The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.